期刊文献+

反相高效液相色谱法测定人血清中西洛他唑质量浓度

Determination of Cilostazol in Human Serum by RP-HPLC
下载PDF
导出
摘要 目的建立测定人血清中西洛他唑质量浓度的反相高效液相色谱(RP-HPLC)法。方法采用液-液萃取高效液相色谱紫外检测法,以地西泮为内标,色谱柱为Phenomenex Synergi 4u Fusion-RPC18柱(250mm×4.6mm,5μm),流动相为乙腈-水(45∶55),流速1.0mL/min,检测波长258nm。结果血清中内源性物质不干扰西洛他唑的检测,西洛他唑质量浓度的线性范围为0.016~2.000μg/mL,日内、日间精密度的RSD均小于15%,低、中、高质量浓度(0.031,0.250,1.000μg/mL)溶液的平均提取回收率分别为76.8%,78.5%,77.1%。结论RP-HPLC法快速、简单、准确,符合生物样品检测要求,可用于临床药代动力学研究。 Objective To develop a rapid, simple and specific HPLC method for determination of cilostazol in human serum. Methods RP- HPLC was used. The analyte and diazapam, used as the internal standard, were analyzed on the Phenomenex Synergi 4u Fusion- RP C18 (250 mm × 4.6 mm, 5 μm) column at the wavelength of 258 nm after liquid - liquid extraction. Acetonitrile - water (45 : 55, V/ V) was used as the isocratic mobile phase at a flow rate of 1.0 mL/min. Results The assay was linear over the concentration range of 0.016- 2.000 μg/mL excluded from endogenous substance effect. RSD for the intra- day and inter- day precision over the entire concentration range was less than 15%. The mean extraction recovery rates of cilostazol were 76. 8%, 78.5%, 77.1% at the concentrations of 0. 031, 0. 250, 1. 000 μg/mL, respectively. Conclusion This RP-HPLC method is simple, rapid and specific to determine cilostazol in human serum for clinical pharmacokinetics.
出处 《中国药业》 CAS 2009年第13期16-17,共2页 China Pharmaceuticals
关键词 西洛他唑 反相高效液相色谱法 药代动力学 cilostazol RP - HPLC pharmacokinetics
  • 相关文献

参考文献5

二级参考文献12

  • 1许禄,化学计量学方法,1995年
  • 2萧参,中国药学杂志,1993年,28卷,425页
  • 3WOO SK, KANG WK, KWON KI. Pharmacokinetic and pharmacodynamic modeling of the antiplatelet and cardiovascular effects of cilostazol in healthy humans[J]. Clin Pharmacol Ther, 2002,71(4):246-252.
  • 4TATA PN, FU CH, BROWDER NJ, et al. The quantitative determination of cilostazol and its four metabolites in human liver minrosomal incubation mixtures by high-performance liquid chromatography[J]. J Pharm Biomed Anal, 1998,18(3):441-451.
  • 5BRAMER SL, TATA PN, VENGURLEKAR SS, et al. Method for the quantitative analysis of cilostazol and its metabolites in human plasma using LC/MS/MS[J]. J Pharm Biomed Anal, 2001, 26(4):637-650.
  • 6Strandness ED,Dalman RL,Steve PS,et al.Effect of cilostazol in patients with intermittent claudication:a randomized,doubleblind,placebo-controlled study[J].Vase Endovasc Surg,2002,36:83.
  • 7Woo SK,Kang WK,Kwon KI.Pharmacokinetic modeling of the antiplatelet and cardjovascular effects of cilostazol in healthy humans[J ].Clin Pharmacol Ther,2002,71:246.
  • 8YAOH.Cilostazol:New treatment forintermittent claudication[J].中国药学杂志,2000,35(4):278-279.
  • 9KAMBAYASHI J,LIU Y,SUN B,et al.Cilostazol as a unique antithrombotic agent[J].CurrPharm Des,2003,9(28):2289-2291.
  • 10FUCJ,TATA P N,OKADA K,etal.Simultaneous quantitative determination of cilostazol andits metabolites in human plasma by highperformance liquid chromatography[J].J Chromatogr BBiomed Sci Appl,1999,28(2):251-262.

共引文献588

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部